<DOC>
	<DOCNO>NCT01015261</DOCNO>
	<brief_summary>Patients newly diagnose Acute lymphoblastic leukemia provide consent , screen eligibility . Eligible patient treat Vincristine ( 1 mg/m2 Day 1 Day 8 ) , Dexamethasone 24 mg/d day 1-15 IT Days 1 , 4 , 8 12 . At day 14 patient randomized two group . BMT group donor Chemotherapy group n't suitable donor . BMT group treat allogenic Bone Marrow Transplantation Chemotherapy treat Cyclophosphamide day 15 , Daunorubicin day 15-18 , Vincristine day 15 22 Dexamethasone day 12-28 follow standard chemotherapy . In BMT group patient receive CNS radiotherapy +100 day transplantation .</brief_summary>
	<brief_title>Allogenic Bone Marrow Transplantation ( BMT ) Compare With Cytoreduction Chemotherapy Acute Lymphoblastic Leukemia ( ALL ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Diagnose Acute lymphoblastic leukemia Age 16 50 year New case ALL Primary CNS involvement Primary Testis involvement Previously treat</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>ALL</keyword>
	<keyword>BMT</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Allogenic</keyword>
</DOC>